Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Promontory Therapeutics to Participate in Business Development Strategies Panel at the Sachs 9th Annual Immuno-Oncology Innovation Forum | ||
By: PR Newswire Association LLC. - 31 May 2023 | Back to overview list |
|
The company will also present an update on its corporate and clinical progress at the event NEW YORK, May 31, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, will participate in a panel discussion on maximizing value in a capital efficient manner at the Sachs 9th Annual Immuno-Oncology Innovation Forum, taking place June 2, 2023 in Chicago. The company will also provide a presentation on its corporate and clinical progress with lead therapeutic candidate, PT-112, a small molecule immunotherapy. Panel Discussion Details Corporate Presentation Details More information about the event and agenda is available on the Sachs Forum website. About Promontory Therapeutics To learn more about Promontory Therapeutics, visit the company's website here. CONTACTS: Promontory Therapeutics Investors: ICR Westwicke Media: View original content to download multimedia:https://www.prnewswire.com/news-releases/promontory-therapeutics-to-participate-in-business-development-strategies-panel-at-the-sachs-9th-annual-immuno-oncology-innovation-forum-301839068.html SOURCE Promontory Therapeutics Inc. |
||
|
||
Copyright 2023 PR Newswire Association LLC. | Back to overview list |